Organization
University Medicine Greifswald, Pediatric Hematology and Oncology
3 abstracts
Abstract
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.Org: Children’s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung GmbH, Schneider Children‘s Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Paediatric Haematology Oncology, Jagiellonian University Medical College, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, Karolinska Institutet, Childhood Cancer Research Unit,
Abstract
Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.Org: University Hospital of Regensburg, University Medicine Greifswald, Pediatric Hematology and Oncology, University Medical Center Dresden, University of Jena, University Children's Hospital,
Abstract
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).Org: University Medicine Greifswald, Pediatric Hematology and Oncology, Pediatric Hematology and Oncology, Greifswald, Germany, Pediatric Hematology and Oncology,